Sufenta


Also found in: Dictionary.
Related to Sufenta: Sufentanil, sufentanil citrate

SUFentanil

(soo-fen-ta-nil) ,

Sufenta

(trade name)

Classification

Therapeutic: opioid analgesics
Pharmacologic: opioid agonists
Pregnancy Category: C

Indications

Intravenous: Analgesic supplement to general anesthesia; usually with other agents (ultra–short-acting barbiturates, neuromuscular blockers, and inhalation anesthetics) to produce balanced anesthesia in patients who are intubated and ventilated.Induction/maintenance of anesthesia (with oxygen or oxygen/nitrous oxide and a neuromuscular blocker). Epidural: Obstetrical pain during labor and vaginal delivery (in combination with bupivacaine). Epidural: Postoperative pain.

Action

Binds to opioid receptors in the CNS, altering the response to and perception of pain.
Produces CNS depression.

Therapeutic effects

Supplement in anesthesia.
Decreased pain.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.
Distribution: Does not readily penetrate adipose tissue; crosses the placenta, enters breast milk.
Metabolism and Excretion: Mostly metabolized by the liver; some metabolism in small intestine; ↓ in neonates, further ↓ in neonates with cardiovascular disease.
Half-life: 2.7 hr (↑ during cardiopulmonary bypass; ↑ in neonates, further ↑ in neonates with cardiovascular disease).

Time/action profile (analgesia†)

ROUTEONSETPEAKDURATION
Epiduralunknownunknown70–90 min
IVwithin 1 minunknown5 min
†Respiratory depression may last longer than analgesia

Contraindications/Precautions

Contraindicated in: Hypersensitivity; cross-sensitivity among agents may occur; Known intolerance.
Use Cautiously in: Diabetes; Severe pulmonary or hepatic disease; CNS tumors; ↑ intracranial pressure; Head trauma; Adrenal insufficiency; Undiagnosed abdominal pain; Hypothyroidism; Alcoholism; Cardiac disease (arrhythmias); Geriatric: Geriatric, debilitated, or critically ill patients; Obstetric / Lactation / Pediatric: Pregnancy, lactation, and children (clearance is ↓ in neonates and further ↓ in neonates with cardiovascular disease, adjust dose accordingly; has been used during labor and cesarean section—drowsiness may occur in infant).

Adverse Reactions/Side Effects

Central nervous system

  • confusion
  • paradoxical excitation/delirium
  • postoperative depression
  • postoperative drowsiness

Ear, Eye, Nose, Throat

  • blurred/double vision

Respiratory

  • apnea (life-threatening)
  • cardiac arrest (life-threatening)
  • laryngospasm (life-threatening)
  • allergic bronchospasm
  • respiratory depression

Cardiovascular

  • arrhythmias
  • bradycardia
  • circulatory depression
  • hypotension

Gastrointestinal

  • biliary spasm
  • nausea/vomiting
  • constipation

Dermatologic

  • facial itching

Musculoskeletal

  • skeletal and thoracic muscle rigidity

Miscellaneous

  • allergic reactions including anaphylaxis (life-threatening)

Interactions

Drug-Drug interaction

Avoid use in patients who have received MAO inhibitors within the previous 14 days (may produce unpredictable, potentially fatal reactions).↑ CNS and respiratory depression with other CNS depressants, including alcohol, antihistamines, antidepressants, other sedative/hypnotics, and other opioids.↑ risk of hypotension with benzodiazepines.Cimetidine, erythromycin, or other agents that decrease hepatic metabolism may prolong duration of recovery.Nalbuphine, buprenorphine, or pentazocine may ↓ analgesia.

Route/Dosage

Low-Dose Anesthesia Adjunct
Intravenous (Adults) 0.5–2 mcg/kg initially, supplemental doses of 10–25 mcg may be given as needed (not to exceed 1 mcg/kg/hr when administered with nitrous oxide and oxygen).
Moderate-Dose Anesthesia Adjunct
Intravenous (Adults) 2–8 mcg/kg initially, supplemental doses of 10–50 mcg may be given as needed (not to exceed 1 mcg/kg/hr when administered with nitrous oxide and oxygen).
Primary Anesthesia (with 100% Oxygen)
Intravenous (Adults) 8–30 mcg/kg initially, supplemental doses of 25–50 mcg may be given as needed or a continuous infusion may be used.
Intravenous (Children) Cardiovascular surgery—10–25 mcg/kg initially, followed by maintenance doses of up to 25–50 mcg; clearance in neonates is ↓ and more ↓ in neonates with cardiovascular disease, adjust dose accordingly.
Obstetrical analgesia
Epidural (Adults) 10–15 mcg in combination with 10 mL of 0.0125% bupivacaine; may be repeated after one hour for two additional doses.
Postoperative pain (unlabeled)
Epidural (Adults) 30–60 mcg in 10 mL of 0.9% sodium chloride; additional doses of 25 mcg may be given hourly if needed.

Availability (generic available)

Injection: 50 mcg/mL

Nursing implications

Nursing assessment

  • Monitor respiratory rate and BP frequently throughout therapy. Report significant changes immediately. The respiratory depressant effects of sufentanil may last longer than the analgesic effects. Monitor closely.
  • Intravenous: Epidural: Assess type, location, and intensity of pain before and 3–5 min after IV administration when sufentanil is used to treat pain.
  • Lab Test Considerations: May cause ↑ serum amylase and lipase concentrations.
  • Symptoms of toxicity include respiratory depression, hypotension, arrhythmias, bradycardia, and asystoleAtropine may be used to treat bradycardia. If respiratory depression persists after surgery, prolonged mechanical ventilation may be required. If an opioid antagonist is required to reverse respiratory depression or coma, naloxone (Narcan) is the antidote. Dilute the 0.4-mg ampule of naloxone in 10 mL of 0.9% NaCl and administer 0.5 mL (0.02 mg) by direct IV push every 2 min. For children and patients weighing <40 kg, dilute 0.1 mg of naloxone in 10 mL of 0.9% NaCl for a concentration of 10 mcg/mL and administer 0.5 mcg/kg every 1–2 min. Titrate dose to avoid withdrawal, seizures, and severe pain. Administration of naloxone in these circumstances, especially in cardiac patients, has resulted in hypertension and tachycardia, occasionally causing left ventricular failure and pulmonary edema.

Potential Nursing Diagnoses

Acute pain (Indications)
Ineffective breathing pattern (Adverse Reactions)
Risk for injury (Side Effects)

Implementation

  • high alert: Accidental overdosage of opioid analgesics has resulted in fatalities. Before administering, clarify all ambiguous orders; have second practitioner independently check original order, dose calculations, and infusion pump settings.
  • Do not confuse sufentanil with fentanyl.
    • Benzodiazepines may be administered before or after administration of sufentanil to reduce the induction dose requirements, decrease the time to loss of consciousness, and produce amnesia. This combination may also increase the risk of hypotension.
    • high alert: Opioid antagonists, oxygen, and resuscitative equipment should be readily available during the administration of sufentanil. Sufentanil should be administered IV only in monitored anesthesia care settings (operating room, emergency department, ICU) with immediate access to life support equipment and should be administered only by personnel trained in resuscitation and emergency airway management.
  • Intravenous Administration
  • Diluent: Administer undiluted.
  • Rate: Administer slowly over 1–3 min. Slow IV administration may reduce the incidence and severity of muscle rigidity, bradycardia, or hypotension. Neuromuscular blocking agents may be administered concurrently to decrease muscle rigidity.
  • Intermittent Infusion: Diluent: May be diluted with D5W or 0.9% NaCl.
  • Rate: Adjust rate based upon the induction dose so that total dose does not exceed 1 mcg/kg per hour of expected surgical time.
  • Y-Site Compatibility: acyclovir, alemtuzumab, alfentanil, amikacin, aminocaproic acid, aminophylline, amphotericin B cholesteryl, amphotericin B lipid complex, amphotericin B liposome, anidulafungin, argatroban, ascorbic acid, atracurium, atropine, azathioprine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride, calcium gluconate, carboplatin, carmustine, caspofungin, cefazolin, cefepime, cefoperazone, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, chloramphenicol, chlorpromazine, cisatracurium, cisplatin, clindamycin, cyanocobalamin, cyclophosphamide, cyclosporine, cytarabine, dactinomycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doxacurium, doxorubicin, doxycycline, enalaprilat, ephedrine, epinephrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etomidate, etoposide, etoposide phosphate, famotidine, fenoldopam, fentanyl, fluconazole, fludarabine, fluorouracil, folic acid, furosemide, ganciclovir, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hetastarch, hydrocortisone, idarubicin, ifosfamide, imipenem/cilastatin, insulin, irinotecan, isoproterenol, ketamine, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methotrexate, methoxamine, methyldopate, methylprednisolone, metoclopramide, metoprolol, metronidazole, miconazole, midazolam, milrinone, minocycline, mitoxantrone, morphine, multivitamins, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, papaverine, pemetrexed, penicillin G, pentamidine, pentazocine, pentobarbital, phenobarbital, phentolamine, phenylephrine, phytonadione, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxime, quinupristin/dalfopristin, ranitidine, remifentanil, rocuronium, scopolamine, sodium acetate, sodium bicarbonate, streptokinase, succinylcholine, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trimetaphan, vancomycin, vasopressin, vecuronium, verapamil, vincristine, vinorelbine, voriconazole, zoledronic acid
  • Y-Site Incompatibility: amphotericin B colloidal, dantrolene, daptomycin, diazoxide, indomethacin, lorazepam, phenytoin, thiopental, trimethoprim/sulfamethoxazole

Patient/Family Teaching

  • Discuss the use of anesthetic agents and the sensations to expect with the patient before surgery.
  • Explain pain assessment scale to patient.
  • Caution patient to change positions slowly to minimize orthostatic hypotension.
  • May causes dizziness and drowsiness. Advise patient to call for assistance during ambulation and transfer and to avoid driving or other activities requiring alertness for 24 hr after administration during outpatient surgery.
  • Instruct patient to avoid alcohol or other CNS depressants for 24 hr after administration for outpatient surgery.

Evaluation/Desired Outcomes

  • General quiescence.
    • Reduced motor activity.
  • Pronounced analgesia.

Sufenta

a trademark for an opioid analgesic used in balanced anesthesia (sufentanil citrate).
References in periodicals archive ?
Two product approvals were received from the FDA: Bal-in-Oil injection and BSS Ophthalmic Solution, and three products were launched: Bal-in-Oil, Sufenta, and Sublimaze.
These acquisitions included ophthalmic products Paremyd, Fluress, Ful-Glo and Rose Bengal from Allergan; Ocusert Pilo-20 and Pilo-40 from Alza and injectable products Sufenta and Alfenta from Janssen Pharmaceutica.
These acquisitions included ophthalmic products Paremyd, Ocusert Pilo-20 and Pilo-40 and injectable products Sufenta and Alfenta.